Publication
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.
Attaya Suvannasankha, Mengying Li, Omonefe Omofuma, Christian Hampp, Matthew Phelan, Alexander Breskin, Ping Shao, Tito Roccia, Nandita Mukherjee, Anju Shrestha, Daniel Lee, Jacob Glass, Glenn S Kroog, Karen Rodriguez Lorenc
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma who received chimeric antigen receptor T-cell (CAR T) therapy versus other systemic anticancer therapies (SACT). EXPERIMENTAL DESIGN: Adult patients with multiple myeloma who…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available